Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_4
2
50%
Ph phase_2
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed250%
terminated125%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_4

Ulipristal for Endometriosis-related Pelvic Pain

NCT02213081
terminatedphase_1

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

NCT03342859
completedphase_2

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

NCT02465814
unknownphase_4

Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy

NCT02288130

Clinical Trials (4)

Showing 4 of 4 trials
NCT02213081Phase 4

Ulipristal for Endometriosis-related Pelvic Pain

Completed
NCT03342859Phase 1

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Terminated
NCT02465814Phase 2

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

Completed
NCT02288130Phase 4

Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4